Abstract:This article explores the role of chirality in macrophage fate and tissue regeneration. It demonstrates that chirality‐dependent wilms tumor 1 associated protein expression orchestrates reciprocal control over m6A methylation in macrophages, specifically mediated by the CCM3‐FAK pair, and this mediation is regulated through chiral‐selective integrin activation. Significantly, L‐nanofibrils demonstrate greater contribution to tissue regeneration. Chirality, a fundamental design feature at all levels of life organization, has shown great capability in guiding cell‐fate determination and tissue regeneration. Chirality‐directed differentiation programs involve remarkable changes in transcriptional networks, yet whether epigenetic regulatory events are also required is less well understood. Herein, by combining high‐throughput m6A MeRIP sequencing, RIP‐qPCR, and gene modulation techniques, it is demonstrated that biomimetic chiral nanofibrils can bidirectionally regulate wilms tumor 1 associated protein (WTAP)‐mediated m6A RNA methylation to guide macrophages polarization for tissue regeneration. The biomimic chiral nanofibril hydrogels are fabricated using a self‐assembly approach based on C2‐symmetric phenylalanine derivatives. In vitro and in vivo studies indicated that the L‐nanofibrils exhibit a greater propensity to promote M2‐macrophage polarization than D‐nanofibrils, thereby favoring osteogenesis. Then, m6A‐MeRIP sequencing revealed a unique chirality‐dependent m6A methylation level in macrophages, which was gated by a competitive pair of CCM3‐FAK through enantioselectively integrin recognition. L‐nanofibrils considerably suppressed WTAP‐mediated m6A methylation by promoting Itgα3‐FAK expression and paxillin‐driven mechanotransduction, whereas D‐nanofibrils induced WTAP‐mediated m6A methylation by favoring ItgαV‐CCM3 expression and suppressing mechanotransduction. Furthermore, the gain‐of‐function and loss‐of‐function experiments and RIP‐qPCR demonstrate that the WTAP expression could direct macrophage polarization via manipulating the functional molecule B7‐H3 (CD276). Thus, a mechano‐epigenetic mechanism of chirality‐mediated cell‐fate determination is unveiled, which holds remarkable promise in the realm of assisted regenerative material design.

Chirality Bias Tissue Homeostasis by Manipulating Immunological Response

Dynamics of Multicellular Swirling on Micropatterned Substrates.

Chirality Regulates Macrophage Polarization for Tissue Regeneration Through Bidirectionally Modulating WTAP‐Mediated m6A Modification

Biomimetic Chiral Nanotopography for Manipulating Immunological Response

Enantiomer-dependent immunological response to chiral nanoparticles

Chirality-Dependent Reprogramming of Macrophages

3D Chiral Self‐Assembling Matrixes for Regulating Polarization of Macrophages and Enhance Repair of Myocardial Infarction

Chirality-biased protein expression profile during early stages of bone regeneration

NIR‐triggered Hydrogel with Dynamic Stiffness Via Ion Chelation to Modulate Macrophage Phenotypes

Chiral Cell Nanomechanics Originated in Clockwise/Counterclockwise Biofunctional Microarrays to Govern the Nuclear Mechanotransduction of Mesenchymal Stem Cells

Chirality-Dependent Reprogramming of Macrophages by Chiral Nanozymes.

Chiral-Selective Antigen-Presentation by Supramolecular Chiral Polymer Micelles

Interface Chirality: From Biological Effects to Biomedical Applications

Taking chiral polymers toward immune regulation

Regulation of Macrophage Polarization on Chiral Potential Distribution of CFO/P(VDF-TrFE) Films.

Chiral Coating-Mediated Interactions of Bacteria with Diverse Biointerfaces

The Effect of Chirality on Cell Spreading and Differentiation: From Chiral Molecules to Chiral Self-Assembly.

Shining light on chiral inorganic nanomaterials for biological issues

Chiral inorganic nanomaterials: Harnessing chirality-dependent interactions with living entities for biomedical applications

Chiral inorganic nanomaterials for biomedical applications

The Development of Chiral Nanoparticles to Target NK Cells and CD8 + T Cells for Cancer Immunotherapy